$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks. Here are some top stocks in the sector climbing on drug trial and earnings news: $Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap. $Ligand Pharmaceuticals (LGND.US)$gained 23%...
Beam Therapeutics' CEO, John Evans showed confidence in Ms. Shaw's ability to turn scientific innovations into commercial treatments. Shaw recognizes Beam's groundbreaking work in genetic medicine and gene editing, predicting major clinical milestones ahead thanks to the company's comprehensive platform and capabilities.
The first treatment based on CRISPR technology is poised to win FDA approval next month, offering hope to patients and opportunities to investors. "A turning point in medicine" Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
Analysts convey bullish views on the company's prospects, with reduced estimated losses and upgraded revenue estimates. However, issues like dilutive stock issuance hint at potential risks.
$Beam Therapeutics(BEAM.US)$Press Release: Beam Announces Agreement for Lilly to Acquire Beam's Opt-In Rights to Verve Therapeutics' Base Editing Programs for Cardiovascular Disease Dow Jones· 2 mins ago
Citi analyst anticipates FDA experts will favor exa-cel, following last year's positive feedback on Zynteglo and Skysona. Beam shares may see a 10%-30% lift post favorable FDA comments. Predicts a promising future for Editas Medicine based on upcoming AdCom and expected data readout for EDIT-301.
Beam Therapeutics股票讨论区
专栏Biotechnology Stocks Climbing on Earnings and Test Results: What to Watch
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
专栏Gene Editing: Is This "Turning Point in Medicine" a Potential Source of Blockbuster Revenue?
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
A bit more
Dow Jones· 4 mins ago
Nice!
Update
Dow Jones· 2 mins ago
暂无评论